Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash from Investing Activities (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Cash from Investing Activities for 13 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 66.21% year-over-year to $5.0 million, compared with a TTM value of $43.4 million through Dec 2025, down 54.57%, and an annual FY2025 reading of $43.4 million, down 54.57% over the prior year.
  • Cash from Investing Activities was $5.0 million for Q4 2025 at Karyopharm Therapeutics, up from $4.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $51.3 million in Q2 2024 and bottomed at -$65.3 million in Q4 2022.
  • Average Cash from Investing Activities over 5 years is $9.2 million, with a median of $15.0 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities crashed 312.21% in 2022, then surged 197.25% in 2024.
  • Year by year, Cash from Investing Activities stood at $30.8 million in 2021, then plummeted by 312.21% to -$65.3 million in 2022, then surged by 141.11% to $26.8 million in 2023, then tumbled by 44.88% to $14.8 million in 2024, then crashed by 66.21% to $5.0 million in 2025.
  • Business Quant data shows Cash from Investing Activities for KPTI at $5.0 million in Q4 2025, $4.8 million in Q3 2025, and $18.3 million in Q2 2025.